RxDoctor Payments Data

Son Do, MD

Gastroenterology · Plano, TXNPI 1871552224

Payments from drug & device makers

$109,637in general payments, 2019–2025

Across 929 payments — averaging $118.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$88K
  • AbbVie$8K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Johnson & Johnson$1K
  • GSK$1K
  • plus $7K from 44 others

What the payments were for

  • Consulting fees$6,0806%
  • Speaking & faculty fees$77,32073%
  • Travel & lodging$2,7783%
  • Food & beverage$19,89919%
  • Education$880%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$109,637 in reported general payments places this provider in the 90th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$89,780
Medicare patients
356
Services billed
703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VemlidyTenofovir Alafenamide184$290,281
LinzessLinaclotide35$46,715
XifaxanRifaximin13$39,071
Mesalamine25$23,526
Entecavir71$21,502
Dexlansoprazole DrDexlansoprazole36$9,843
Omeprazole384$8,066
Esomeprazole Magnesium133$7,373
Tenofovir Disoproxil Fumarate55$6,244
Lansoprazole102$4,183
Ursodiol19$3,951
Famotidine181$3,661
Rabeprazole Sodium52$3,140
Dicyclomine Hcl86$2,663
Pantoprazole Sodium153$1,637

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$88,380$290,281184 claims
AbbVieLinzess$8,003$46,71535 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,734$39,07113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →